Bacillus clausii

Generic Medicine Info
Indications and Dosage
Adult: As 2x109 spores/5 mL oral suspension or 2x109 spores/capsule: 2-3 vials or capsules daily at 3-4 hours intervals.
Child: 1 month to 11 years As 2x109 spores/5 mL oral suspension: 1-2 vials daily at 3-4 hours intervals, diluting in sweetened water, milk, tea or orange juice.
Special Precautions
Immunocompromised patients (e.g. premature infants). Children. Pregnancy and lactation. Not intended for inj or administration in any other way.
Adverse Reactions
Immune system disorders: Hypersensitivity reactions (e.g. rash, urticaria, angioedema).
Patient Counseling Information
Administer in the interval between 1 dose of antibiotic and the next during antibiotic treatment.
Description: Bacillus clausii, a probiotic, is a spore-forming bacterium part of the normal gut flora with no pathogenic properties. It inhibits the growth of pathogens in the gastrointestinal tract via 3 distinct mechanism: colonisation, immunostimulation and antimicrobial properties. Bacillus clausii spores have high resistance to acidic conditions of the stomach and can reach the intestinal tract intact wherein they are transformed into metabolically active vegetative cells; they also contribute to restore the balance of the intestinal bacterial flora. Bacillus clausii is also capable of producing vitamins, particularly the group B vitamins, which contribute to correct the dysvitaminosis caused by use of antibiotics and chemotherapeutic agents.
Oral suspension: Store below 30°C. Cap: Store below 25°C.
MIMS Class
Jayanthi N and Ratna Sudha M. Bacillus clausii - The Probiotic of Choice in the Treatment of Diarrhoea. 5(4):1-4. doi: 10.4172/2157-7595.1000211. Accessed 18/07/2019

Anon. Bacillus clausii. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 18/07/2019.

Erceflora (Sanofi S.p.A.). MIMS Philippines. Accessed 18/07/2019.

Disclaimer: This information is independently developed by MIMS based on Bacillus clausii from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in